228,064 Kenvue Inc. $KVUE Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 4.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,831,309 shares of the company’s stock after selling 228,064 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.25% of Kenvue worth $85,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Kenvue during the third quarter valued at $10,845,000. Vise Technologies Inc. raised its position in shares of Kenvue by 16.0% in the 3rd quarter. Vise Technologies Inc. now owns 35,217 shares of the company’s stock worth $622,000 after purchasing an additional 4,864 shares during the last quarter. Cidel Asset Management Inc. boosted its stake in Kenvue by 5.4% in the 3rd quarter. Cidel Asset Management Inc. now owns 19,288 shares of the company’s stock worth $341,000 after purchasing an additional 988 shares in the last quarter. Americana Partners LLC boosted its stake in Kenvue by 3.7% in the 3rd quarter. Americana Partners LLC now owns 51,160 shares of the company’s stock worth $903,000 after purchasing an additional 1,825 shares in the last quarter. Finally, North Dakota State Investment Board boosted its stake in Kenvue by 2.8% in the 3rd quarter. North Dakota State Investment Board now owns 58,063 shares of the company’s stock worth $1,025,000 after purchasing an additional 1,558 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Kenvue

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Kimberly-Clark is targeting $2.1 billion in annual synergies from the acquisition, creating potential for meaningful cost savings over time. Those savings are a possible long-term positive for the combined business, though delivery and timing remain to be seen. Kimberly-Clark completes Kenvue acquisition and targets $2.1 billion in annual synergies
• Neutral Sentiment: The deal is complete, and trading in KVUE was halted when the merger became effective. The closing removes uncertainty about the transaction, but Kenvue’s future as part of Kimberly-Clark may change how investors assess its standalone results. Kimberly-Clark completes acquisition of Kenvue
• Neutral Sentiment: UBS raised its price target to $20 from $19 but kept a neutral rating, suggesting limited near-term upside in its view. UBS Group stock recommendations
• Negative Sentiment: Kenvue’s departure from the S&P 500 may prompt index-tracking funds to sell shares, potentially adding technical selling pressure around the transition. Kenvue is leaving the S&P 500
• Negative Sentiment: ETFs were net sellers of KVUE on Oct. 30, a potential source of near-term selling pressure, although the data predates the merger’s completion. ETFs are net sellers of Kenvue on Oct. 30

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent analyst reports. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. UBS Group raised their price target on shares of Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research report on Monday. HSBC decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Finally, Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Ten analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.29.

Kenvue Trading Up 0.5%

Shares of KVUE stock opened at $19.41 on Wednesday. Kenvue Inc. has a 12-month low of $14.06 and a 12-month high of $20.13. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $18.41 and its 200 day moving average is $18.21. The stock has a market capitalization of $37.28 billion, a P/E ratio of 22.06, a P/E/G ratio of 1.77 and a beta of 0.48.

Kenvue (NYSE:KVUE) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.29. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.86 billion. During the same period in the previous year, the business earned $0.28 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. Kenvue’s dividend payout ratio is currently 95.45%.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.